Scolaris Content Display Scolaris Content Display

Gases para el establecimiento del neumoperitoneo durante la cirugía abdominal laparoscópica

This is not the most recent version

Appendices

Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy

#1 MeSH descriptor: [Surgical Procedures, Minimally Invasive] explode all trees

#2 MeSH descriptor: [Laparoscopy] explode all trees

#3 MeSH descriptor: [Video‐Assisted Surgery] explode all trees

#4 (laparoscop* or coelioscop* or celioscop* or peritoneoscop* or minimally invasive or video assisted surgery)

#5 (#1 or #2 or #3 or #4)

#6 MeSH descriptor: [Carbon Dioxide] explode all trees

#7 MeSH descriptor: [Nitrogen Oxides] explode all trees

#8 MeSH descriptor: [Nitrogen] explode all trees

#9 MeSH descriptor: [Argon] explode all trees

#10 MeSH descriptor: [Helium] explode all trees

#11 (gas* or carbon dioxide or CO2 or nitrous oxide or laughing gas or N2O or nitrogen or N2 or helium or argon)

#12 (#6 or #7 or #8 or #9 or #10 or #11)

#13 MeSH descriptor: [Pneumoperitoneum] explode all trees

#14 (pneumoperitoneum*)

#15 (#13 or #14)

#16 (#5 and #12 and #15)

Appendix 2. MEDLINE (Ovid) search strategy

1. exp Surgical Procedures, Minimally Invasive/

2. exp Laparoscopy/

3. exp Video‐Assisted Surgery/

4. (laparoscop* or coelioscop* or celioscop* or peritoneoscop* or minimally invasive or video assisted surgery).mp.

5. 1 or 2 or 3 or 4

6. exp Carbon Dioxide/

7. exp Nitrogen Oxides/

8. exp Nitrogen/

9. exp Argon/

10. exp Helium/

11. (gas* or carbon dioxide or CO2 or nitrous oxide or laughing gas or N2O or nitrogen or N2 or helium or argon).mp.

12. 6 or 7 or 8 or 9 or 10 or 11

13. exp Pneumoperitoneum/

14. pneumoperitoneum*.mp.

15. 13 or 14

16. 5 and 12 and 15

17. randomized controlled trial.pt.

18. controlled clinical trial.pt.

19. randomized.ab.

20. placebo.ab.

21. clinical trial as topic.sh.

22. randomly.ab.

23. trial.ti.

24. 17 or 18 or 19 or 20 or 21 or 22 or 23

25. exp animals/ not humans.sh.

26. 24 not 25

27. 16 and 26

Appendix 3. Embase (Ovid) search strategy

1. exp minimally invasive surgery/

2. exp laparoscopy/

3. (laparoscop* or coelioscop* or celioscop* or peritoneoscop* or minimally invasive or video assisted surgery).mp.

4. 1 or 2 or 3

5. exp carbon dioxide/

6. exp nitrous oxide/

7. exp nitrogen/

8. exp argon/

9. exp helium/

10. exp gas/

11. (gas* or carbon dioxide or CO2 or nitrous oxide or laughing gas or N2O or nitrogen or N2 or helium or argon).mp.

12. 5 or 6 or 7 or 8 or 9 or 10 or 11

13. exp pneumoperitoneum/

14. pneumoperitoneum*.mp.

15. 13 or 14

16. 4 and 12 and 15

17. CROSSOVER PROCEDURE.sh

18. DOUBLE‐BLIND PROCEDURE.sh

19. SINGLE‐BLIND PROCEDURE.sh

20. (crossover* or cross over*).ti,ab.

21. placebo*.ti,ab.

22. (doubl* adj blind*).ti,ab.

23. allocate*.ti,ab.

24. trial.ti.

25. RANDOMIZED CONTROLLED TRIAL.sh.

26. random*.ti,ab.

27. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26

28. (exp animal/ or exp invertebrate/ or animal.hw or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or men or wom?n).ti.)

29. 27 not 28

30. 16 and 29

Appendix 4. Science Citation Index Expanded search strategy

#1 Topic=(laparoscop* or coelioscop* or celioscop* or peritoneoscop* or minimally invasive or video assisted surgery)

#2 Topic=(gas* or carbon dioxide or CO2 or nitrous oxide or laughing gas or N2O or nitrogen or N2 or helium or argon)

#3 Topic=(pneumoperitoneum*)

#4 Topic=(randomized or randomised or controlled or trial or clinical or placebo or clinical or randomly or trial)

#5 (#4 AND #3 AND #2 AND #1)

Appendix 5. Criteria for judging risk of bias in the 'Risk of bias' assessment tool

Random sequence generation

Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence.

Criteria for a judgement of 'Low risk' of bias.

The investigators described a random component in the sequence generation process such as:

  • referring to a random number table;

  • using a computer random number generator;

  • coin tossing;

  • shuffling cards or envelopes;

  • throwing dice;

  • drawing of lots;

  • minimisation.*

*Minimisation may be implemented without a random element, and this is considered to be equivalent to being random.

Criteria for the judgement of 'High risk' of bias.

The investigators described a non‐random component in the sequence generation process. Usually, the description would involve some systematic, non‐random approach, e.g.:

  • sequence generated by odd or even date of birth;

  • sequence generated by some rule based on date (or day) of admission;

  • sequence generated by some rule based on hospital or clinic record number.

Other non‐random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of non‐random categorisation of participants, e.g.:

  • allocation by judgement of the clinician;

  • allocation by preference of the participant;

  • allocation based on the results of a laboratory test or a series of tests;

  • allocation by availability of the intervention.

Criteria for the judgement of 'Unclear risk' of bias.

Insufficient information about the sequence generation process to permit judgement of 'Low risk' or 'High risk.'

Allocation concealment

Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.

Criteria for a judgement of 'Low risk' of bias.

Participants and investigators enrolling participants could not have foreseen assignment because 1 of the following, or an equivalent method, was used to conceal allocation:

  • central allocation (including telephone, web‐based and pharmacy‐controlled randomisation);

  • sequentially numbered drug containers of identical appearance;

  • sequentially numbered, opaque, sealed envelopes.

Criteria for the judgement of 'High risk' of bias.

Participants or investigators enrolling participants could possibly have foreseen assignments and thus introduced selection bias, such as allocation based on:

  • using an open random allocation schedule (e.g. a list of random numbers);

  • assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered);

  • alternation or rotation;

  • date of birth;

  • case record number;

  • any other explicitly unconcealed procedure.

Criteria for the judgement of 'Unclear risk' of bias.

Insufficient information to permit judgement of 'Low risk' or 'High risk.' This is usually the case if the method of concealment was not described or not described in sufficient detail to allow a definite judgement; e.g. if the use of assignment envelopes was described, but it remained unclear whether envelopes were sequentially numbered, opaque and sealed.

Blinding of participants and personnel

Performance bias due to knowledge of the allocated interventions by participants and personnel during the study.

Criteria for a judgement of 'Low risk' of bias.

Any 1 of the following:

  • no blinding or incomplete blinding, but the review authors judged that the outcome was not likely to be influenced by lack of blinding;

  • blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

Criteria for the judgement of 'High risk' of bias.

Any 1 of the following:

  • no blinding or incomplete blinding, and the outcome was likely to be influenced by lack of blinding;

  • blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome was likely to be influenced by lack of blinding.

Criteria for the judgement of 'Unclear risk' of bias.

Any 1 of the following:

  • insufficient information to permit judgement of 'Low risk' or 'High risk;'

  • study did not address this outcome.

Blinding of outcome assessment

Detection bias due to knowledge of the allocated interventions by outcome assessors.

Criteria for a judgement of 'Low risk' of bias.

Any 1 of the following:

  • no blinding of outcome assessment, but the review authors judged that the outcome measurement was not likely to be influenced by lack of blinding;

  • blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Criteria for the judgement of 'High risk' of bias.

Any 1 of the following:

  • no blinding of outcome assessment, and the outcome measurement was likely to be influenced by lack of blinding;

  • blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement was likely to be influenced by lack of blinding.

Criteria for the judgement of 'Unclear risk' of bias.

Any 1 of the following:

  • insufficient information to permit judgement of 'Low risk' or 'High risk;'

  • study did not address this outcome.

Incomplete outcome data

Attrition bias due to amount, nature, or handling of incomplete outcome data.

Criteria for a judgement of 'Low risk' of bias.

Any 1 of the following:

  • no missing outcome data;

  • reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);

  • missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;

  • for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;

  • for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;

  • missing data were imputed using appropriate methods.

Criteria for the judgement of 'High risk' of bias.

Any 1 of the following:

  • reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;

  • for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;

  • for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;

  • 'as‐treated' analysis done with substantial departure of the intervention received from that assigned at randomisation;

  • potentially inappropriate application of simple imputation.

Criteria for the judgement of 'Unclear risk' of bias.

Any 1 of the following:

  • insufficient reporting of attrition/exclusions to permit judgement of 'Low risk' or 'High risk' (e.g. number randomised not stated, no reasons for missing data provided);

  • study did not address this outcome.

Selective reporting

Reporting bias due to selective outcome reporting.

Criteria for a judgement of 'Low risk' of bias.

Any of the following:

  • study protocol was available and all of the study's prespecified (primary and secondary) outcomes that were of interest in the review were reported in the prespecified way;

  • study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).

Criteria for the judgement of 'High risk' of bias.

Any 1 of the following:

  • not all of the study's prespecified primary outcomes were reported;

  • ≥ 1 primary outcomes weres reported using measurements, analysis methods, or subsets of data (e.g. subscales) that were not prespecified;

  • ≥ 1 reported primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse effect);

  • ≥ 1 outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis;

  • study report did not include results for a key outcome that would be expected to have been reported for such a study.

Criteria for the judgement of 'Unclear risk' of bias.

Insufficient information to permit judgement of 'Low risk' or 'High risk.' It is likely that the majority of studies will fall into this category.

Other bias

Bias due to problems not covered elsewhere in the table.

Criteria for a judgement of 'Low risk' of bias.

Study appeared to be free of other sources of bias.

Criteria for the judgement of 'High risk' of bias.

There was ≥ 1 important risk of bias; e.g. the study:

  • had a potential source of bias related to the specific study design used; or

  • was claimed to have been fraudulent; or

  • had some other problem.

Criteria for the judgement of 'Unclear risk' of bias.

There may be a risk of bias, but there was either:

  • insufficient information to assess whether an important risk of bias existed; or

  • insufficient rationale or evidence that an identified problem would introduce bias.

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figures and Tables -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figures and Tables -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Trial sequential analysis of nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum for cardiopulmonary complications. Analysis was performed with an event rate of 2.9% (Pc) in the control group, a risk ratio reduction of 20%, alpha 5%, beta 20%, and observed diversity 0%. The accrued sample size was so small that the trial sequential boundaries could not be drawn. The cumulative Z‐curve did not cross the naive 5% statistical boundaries (red horizontal lines). The results showed that the observed diversity‐adjusted required information size was 3781 participants, corresponding to 3.7% of the total sample size in the included trials. Accordingly, the meta‐analysis did not support or refute an intervention effect as data were too few.
Figures and Tables -
Figure 4

Trial sequential analysis of nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum for cardiopulmonary complications. Analysis was performed with an event rate of 2.9% (Pc) in the control group, a risk ratio reduction of 20%, alpha 5%, beta 20%, and observed diversity 0%. The accrued sample size was so small that the trial sequential boundaries could not be drawn. The cumulative Z‐curve did not cross the naive 5% statistical boundaries (red horizontal lines). The results showed that the observed diversity‐adjusted required information size was 3781 participants, corresponding to 3.7% of the total sample size in the included trials. Accordingly, the meta‐analysis did not support or refute an intervention effect as data were too few.

Trial sequential analysis of nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum for surgical morbidity. Analysis was performed with an event rate of 2.8% (Pc) in the control group, a risk ratio reduction of 20%, alpha 5%, beta 20%, and observed diversity 0%. The cumulative Z‐curve did not cross the naive 5% statistical boundaries (red horizontal lines). The results showed that the observed diversity adjusted required information size was 3919 participants, corresponding to 3.6% of the total sample size in the included trials. Accordingly, the meta‐analysis did not support or refute an intervention effect as data were too few.
Figures and Tables -
Figure 5

Trial sequential analysis of nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum for surgical morbidity. Analysis was performed with an event rate of 2.8% (Pc) in the control group, a risk ratio reduction of 20%, alpha 5%, beta 20%, and observed diversity 0%. The cumulative Z‐curve did not cross the naive 5% statistical boundaries (red horizontal lines). The results showed that the observed diversity adjusted required information size was 3919 participants, corresponding to 3.6% of the total sample size in the included trials. Accordingly, the meta‐analysis did not support or refute an intervention effect as data were too few.

Trial sequential analysis of helium pneumoperitoneum versus carbon dioxide pneumoperitoneum for cardiopulmonary complications. Analysis was performed with an event rate of 3.0% (Pc) in the control group, a risk ratio reduction of 20%, alpha 5%, beta 20%, and observed diversity 0%. The cumulative Z‐curve did not cross the naive 5% statistical boundaries (red horizontal lines). The results showed that the observed diversity adjusted required information size was 3651 participants, corresponding to 3.5% of the total sample size in the included trials. Accordingly, the meta‐analysis did not support or refute an intervention effect as data were too few.
Figures and Tables -
Figure 6

Trial sequential analysis of helium pneumoperitoneum versus carbon dioxide pneumoperitoneum for cardiopulmonary complications. Analysis was performed with an event rate of 3.0% (Pc) in the control group, a risk ratio reduction of 20%, alpha 5%, beta 20%, and observed diversity 0%. The cumulative Z‐curve did not cross the naive 5% statistical boundaries (red horizontal lines). The results showed that the observed diversity adjusted required information size was 3651 participants, corresponding to 3.5% of the total sample size in the included trials. Accordingly, the meta‐analysis did not support or refute an intervention effect as data were too few.

Trial sequential analysis of helium pneumoperitoneum versus carbon dioxide pneumoperitoneum for serious adverse events. Analysis was performed with an event rate of 2.3% (Pc) in the control group, a risk ratio reduction of 20%, alpha 5%, beta 20%, and observed diversity 0%. The cumulative Z‐curve did not cross the naive 5% statistical boundaries (red horizontal lines). The results showed that the observed diversity adjusted required information size was 4793 participants, corresponding to 2.7% of the total sample size in the included trials. Accordingly, the meta‐analysis did not support or refute an intervention effect as data were too few.
Figures and Tables -
Figure 7

Trial sequential analysis of helium pneumoperitoneum versus carbon dioxide pneumoperitoneum for serious adverse events. Analysis was performed with an event rate of 2.3% (Pc) in the control group, a risk ratio reduction of 20%, alpha 5%, beta 20%, and observed diversity 0%. The cumulative Z‐curve did not cross the naive 5% statistical boundaries (red horizontal lines). The results showed that the observed diversity adjusted required information size was 4793 participants, corresponding to 2.7% of the total sample size in the included trials. Accordingly, the meta‐analysis did not support or refute an intervention effect as data were too few.

Comparison 1 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 1 Cardiopulmonary complications.
Figures and Tables -
Analysis 1.1

Comparison 1 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 1 Cardiopulmonary complications.

Comparison 1 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 2 Procedure‐related general complications.
Figures and Tables -
Analysis 1.2

Comparison 1 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 2 Procedure‐related general complications.

Comparison 1 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 3 Analgesia requirements.
Figures and Tables -
Analysis 1.3

Comparison 1 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 3 Analgesia requirements.

Comparison 1 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 4 Cardiopulmonary changes.
Figures and Tables -
Analysis 1.4

Comparison 1 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 4 Cardiopulmonary changes.

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 1 Cardiopulmonary complications.
Figures and Tables -
Analysis 2.1

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 1 Cardiopulmonary complications.

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 2 Pneumoperitoneum‐related serious adverse events.
Figures and Tables -
Analysis 2.2

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 2 Pneumoperitoneum‐related serious adverse events.

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 3 Pain scores (cm) (first postoperative day).
Figures and Tables -
Analysis 2.3

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 3 Pain scores (cm) (first postoperative day).

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 4 Analgesia requirements (morphine mg).
Figures and Tables -
Analysis 2.4

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 4 Analgesia requirements (morphine mg).

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 5 Number of participants requiring analgesia.
Figures and Tables -
Analysis 2.5

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 5 Number of participants requiring analgesia.

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 6 Cardiopulmonary parameters.
Figures and Tables -
Analysis 2.6

Comparison 2 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 6 Cardiopulmonary parameters.

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 1 Cardiopulmonary complications.
Figures and Tables -
Analysis 3.1

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 1 Cardiopulmonary complications.

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 2 Pneumoperitoneum‐related serious adverse events.
Figures and Tables -
Analysis 3.2

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 2 Pneumoperitoneum‐related serious adverse events.

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 3 Pain scores (cm) (first postoperative day).
Figures and Tables -
Analysis 3.3

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 3 Pain scores (cm) (first postoperative day).

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 4 Hospital costs (CNY).
Figures and Tables -
Analysis 3.4

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 4 Hospital costs (CNY).

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 5 Cardiopulmonary parameters.
Figures and Tables -
Analysis 3.5

Comparison 3 Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum, Outcome 5 Cardiopulmonary parameters.

Comparison 4 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 1 Cardiopulmonary complications.
Figures and Tables -
Analysis 4.1

Comparison 4 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 1 Cardiopulmonary complications.

Comparison 4 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 2 Procedure‐related general complications.
Figures and Tables -
Analysis 4.2

Comparison 4 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 2 Procedure‐related general complications.

Comparison 4 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 3 Pneumoperitoneum‐related serious adverse events.
Figures and Tables -
Analysis 4.3

Comparison 4 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 3 Pneumoperitoneum‐related serious adverse events.

Comparison 4 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 4 Mortality.
Figures and Tables -
Analysis 4.4

Comparison 4 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 4 Mortality.

Comparison 5 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 1 Cardiopulmonary complications.
Figures and Tables -
Analysis 5.1

Comparison 5 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 1 Cardiopulmonary complications.

Comparison 5 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 2 Procedure‐related general complications.
Figures and Tables -
Analysis 5.2

Comparison 5 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 2 Procedure‐related general complications.

Comparison 5 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 3 Pneumoperitoneum‐related serious adverse events.
Figures and Tables -
Analysis 5.3

Comparison 5 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 3 Pneumoperitoneum‐related serious adverse events.

Comparison 5 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 4 Mortality.
Figures and Tables -
Analysis 5.4

Comparison 5 Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 4 Mortality.

Comparison 6 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 1 Cardiopulmonary complications.
Figures and Tables -
Analysis 6.1

Comparison 6 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 1 Cardiopulmonary complications.

Comparison 6 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 2 Procedure‐related general complications.
Figures and Tables -
Analysis 6.2

Comparison 6 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 2 Procedure‐related general complications.

Comparison 6 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 3 Pneumoperitoneum‐related serious adverse events.
Figures and Tables -
Analysis 6.3

Comparison 6 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 3 Pneumoperitoneum‐related serious adverse events.

Comparison 6 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 4 Mortality.
Figures and Tables -
Analysis 6.4

Comparison 6 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data), Outcome 4 Mortality.

Comparison 7 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 1 Cardiopulmonary complications.
Figures and Tables -
Analysis 7.1

Comparison 7 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 1 Cardiopulmonary complications.

Comparison 7 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 2 Procedure‐related general complications.
Figures and Tables -
Analysis 7.2

Comparison 7 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 2 Procedure‐related general complications.

Comparison 7 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 3 Pneumoperitoneum‐related serious adverse events.
Figures and Tables -
Analysis 7.3

Comparison 7 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 3 Pneumoperitoneum‐related serious adverse events.

Comparison 7 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 4 Mortality.
Figures and Tables -
Analysis 7.4

Comparison 7 Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data, Outcome 4 Mortality.

Summary of findings for the main comparison. Nitrous oxide versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery

Nitrous oxide versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery

Patient or population: people undergoing laparoscopic general abdominal or gynaecological pelvic surgery under general anaesthesia

Setting: secondary and tertiary care

Intervention: nitrous oxide pneumoperitoneum

Comparison: carbon dioxide pneumoperitoneum

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with carbon dioxide pneumoperitoneum

Risk with nitrous oxide pneumoperitoneum

Cardiopulmonary complications

Follow‐up: 0 to 1 month

29 per 1000

57 per 1000
(11 to 302)

RR 2.00
(0.38 to 10.43)

140
(2 studies)

⊕⊝⊝⊝
Very low1,2

Trial sequential analysis showed a diversity‐adjusted required information size of 3781 participants to support or refute nitrous oxide pneumoperitoneum.

Procedure‐related general complications

Follow‐up: 0 to 1 month

28 per 1000

28 per 1000
(5 to 160)

RR 1.01
(0.18 to 5.71)

143
(2 studies)

⊕⊝⊝⊝
Very low1,2

Trial sequential analysis showed a diversity‐adjusted required information size of 3919 participants to support or refute nitrous oxide pneumoperitoneum.

Pneumoperitoneum‐related serious adverse events

Follow‐up: 0 to 1 month

See comment

See comment

Not estimable

196
(3 studies)

⊕⊕⊝⊝
Low3,4

None of the studies reported any pneumoperitoneum‐related serious adverse events.

Mortality

Follow‐up: 0 to 1 month

See comment

See comment

Not estimable

196
(3 studies)

⊕⊕⊝⊝
Low3,4

None of the studies reported any deaths.

Quality of life

None of the studies reported quality of life.

Pain scores (first postoperative day)

VAS, lower score indicates less pain.
Scale: 0 cm to 10 cm

Follow‐up: 1 day

See comment

See comment

Not estimable

140
(2 studies)

⊕⊝⊝⊝
Very low3,4,5

Neither trials reported the standard deviation for pain scores on the VAS scale. Substantial clinical heterogeneity in between the 2 studies.

Analgesia requirements

Follow‐up: 1 week

The mean analgesia requirement in the carbon dioxide pneumoperitoneum was 54.4 mg of oxycodone and 2.0 tablets/24 hours of ibuprofen

The mean analgesia requirement in the nitrous oxide pneumoperitoneum was 0.69 standard deviations lower
(1.42 lower to 0.04 higher)

SMD ‐0.69
(‐1.42 to 0.04)

193
(3 studies)

⊕⊝⊝⊝
Very low3,4,6

Hospital costs

None of the studies reported costs.

*The basis for the assumed risk is the mean comparison group proportion in the studies. The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; RR: risk ratio; SMD: standardised mean difference; VAS: visual analogue scale.

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1 Downgraded two levels for very serious risk of bias.

2 Downgraded one level for serious imprecision (the confidence interval of risk ratio overlapped 0.75 and 1.25, and small sample size).

3 Downgraded one level for serious imprecision (small sample size).

4 Downgraded one level for serious risk of bias.

5 Downgraded one level for indirectness.

6 Downgraded one level for severe inconsistency (substantial heterogeneity as indicated by the I2 statistic).

Figures and Tables -
Summary of findings for the main comparison. Nitrous oxide versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery
Summary of findings 2. Helium versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery

Helium versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery

Patient or population: people undergoing laparoscopic general abdominal or gynaecological pelvic surgery under general anaesthesia

Setting: secondary and tertiary care

Intervention: helium pneumoperitoneum

Comparison: carbon dioxide pneumoperitoneum

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with carbon dioxide pneumoperitoneum

Risk with helium pneumoperitoneum

Cardiopulmonary complications

Follow‐up: 0 to 1 month

30 per 1000

44 per 1000
(10 to 183)

RR 1.46
(0.35 to 6.12)

128
(3 studies)

⊕⊝⊝⊝
Very low1,2

Trial sequential analysis showed a diversity‐adjusted required information size of 3651 participants to support or refute helium pneumoperitoneum.

Procedure‐related general complications

Follow‐up: 0 to 1 month

See comment

See comment

Not estimable

144
(4 studies)

⊕⊝⊝⊝

Very low3,4

None of the studies reported any significant procedure‐related general complications in either group.

Pneumoperitoneum‐related serious adverse events

Follow‐up: 0 to 1 month

0 per 1000

44 per 1000
(0 to 0)

Peto OR 8.28
(0.86 to 80.03)

128
(3 studies)

⊕⊝⊝⊝
Very low1,3,5

Trial sequential analysis showed a diversity‐adjusted required information size of 4793 participants to support or refute helium pneumoperitoneum.

Mortality

Follow‐up: 0 to 1 month

See comment

See comment

Not estimable

144
(4 studies)

⊕⊕⊝⊝
Low1,3

None of the studies reported any deaths.

Quality of life

None of the studies reported quality of life.

Pain scores (first postoperative day)

Visual analogue scale, lower score indicates less pain.
Scale: 0 to 10

Follow‐up: 1 day

The mean pain scores (first postoperative day) in the carbon dioxide pneumoperitoneum was 3.01 cm

The mean pain scores (first postoperative day) in the helium pneumoperitoneum was
0.49 cm higher
(0.28 lower to 1.26 higher)

MD 0.49 (‐0.28 to 1.26)

108
(2 studies)

⊕⊝⊝⊝
Very low1,3,5

Analgesia requirements (morphine mg)

Follow‐up: 2 days

The mean analgesia requirements (morphine) in the carbon dioxide pneumoperitoneum was 36.6 mg

The mean analgesia requirements (morphine) in the helium pneumoperitoneum was 12 mg higher
(4.44 higher to 19.56 higher)

MD 12.00 (4.44 to 19.56)

90
(1 study)

⊕⊝⊝⊝
Very low1,3,5

Hospital costs

None of the studies reported costs.

*The basis for the assumed risk is the mean comparison group proportion in the studies. The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; MD: mean difference; OR: odds ratio; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1 Downgraded one level for serious risk of bias.

2 Downgraded two levels for very serious imprecision (the confidence interval of risk ratio overlapped 0.75 and 1.25, and small sample size).

3 Downgraded one level for serious imprecision (small sample size).

4 Downgraded two levels for very serious risk of bias.

5 Downgraded one level for indirectness.

Figures and Tables -
Summary of findings 2. Helium versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery
Summary of findings 3. Room air versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery

Room air versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery

Patient or population: people undergoing laparoscopic general abdominal or gynaecological pelvic surgery under general anaesthesia

Setting: secondary and tertiary care

Intervention: room air pneumoperitoneum

Comparison: carbon dioxide pneumoperitoneum

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with carbon dioxide pneumoperitoneum

Risk with room air pneumoperitoneum

Cardiopulmonary complications

Follow‐up: 1 month

See comment

See comment

Not estimable

146
(1 study)

⊕⊝⊝⊝
Very low1,2

Trial did not report any cardiopulmonary complications.

Procedure‐related general complications

The study did not report procedure‐related general complications.

Pneumoperitoneum‐related serious adverse events

Follow‐up: 1 month

See comment

See comment

Not estimable

146
(1 study)

⊕⊝⊝⊝
Very low1,2

Trial did not report any pneumoperitoneum‐related serious adverse events.

Mortality

Follow‐up: 1 month

See comment

See comment

Not estimable

146
(1 study)

⊕⊕⊝⊝
Low2,3

The study did not report any deaths.

Quality of life

The study did not report quality of life.

Pain scores (first postoperative day)

Visual analogue scale, lower score indicates less pain.
Scale: 0 to 10 cm

Follow‐up: 1 day

The mean pain scores (first postoperative day) in the carbon dioxide pneumoperitoneum was 2.60 cm

The mean pain scores (first postoperative day) in the room air pneumoperitoneum was
0.80 cm lower
(1.15 lower to 0.45 lower)

MD ‐0.80 (‐1.15 to ‐0.45)

146
(1 study)

⊕⊝⊝⊝
Very low1,2

Analgesia requirements

The study did not report analgesia requirements.

Hospital costs (CNY)

Follow‐up: 1 month

The mean hospital costs in the carbon dioxide pneumoperitoneum was CNY12,012.00

The mean hospital costs in the room air pneumoperitoneum was CNY2667.00 lower
(3275.68 lower to 2058.32 lower)

MD ‐2667.00 (‐3275.68 to ‐2058.32)

146
(1 study)

⊕⊝⊝⊝
Very low1,2

*The basis for the assumed risk is the mean comparison group proportion in the studies. The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; MD: mean difference.

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1 Downgraded two levels for very serious risk of bias.

2 Downgraded one level for serious imprecision (small sample size).

3 Downgraded one level for serious risk of bias.

Figures and Tables -
Summary of findings 3. Room air versus carbon dioxide for establishing pneumoperitoneum during laparoscopic abdominal surgery
Table 1. Sensitivity analysis by changing between worst‐case scenario analysis and best‐case scenario analysis for missing data

Changing between worst‐case scenario analysis and best‐case scenario analysis for missing data

Outcomes

Risk ratio (95% CI)

Main analysis

Worst/best‐case

Best/worst‐case

Cardiopulmonary complications (nitrous oxide vs carbon dioxide)

2.00 (0.38, 10.43)

2.64 (0.64, 10.93)

1.02 (0.27, 3.86)

Procedure‐related general complications/surgical morbidity (nitrous oxide vs carbon dioxide)

1.01 (0.18, 5.71)

1.82 (0.40, 8.31)

0.56 (0.12, 2.58)

Pneumoperitoneum‐related serious adverse events (nitrous oxide vs carbon dioxide)

No events

Peto OR

7.46 (0.47, 119.30)

Peto OR

0.14 (0.01, 2.19)

Mortality (nitrous oxide vs carbon dioxide)

No events

Peto OR

7.46 (0.47, 119.30)

Peto OR

0.14 (0.01, 2.19)

Cardiopulmonary complications (helium vs carbon dioxide)

1.46 (0.35, 6.12)

4.58 (1.21, 17.36)

1.46 (0.35, 6.12)

Procedure‐related general complications/surgical morbidity (helium vs carbon dioxide)

No events

8.47 (1.11, 64.60)

0.20 (0.01, 3.61)

Pneumoperitoneum‐related serious adverse events (helium vs carbon dioxide)

Peto OR

8.28 (0.86, 80.03)

Peto OR

9.19 (2.56, 33.01)

Peto OR

8.28 (0.86, 80.03)

Mortality (helium vs carbon dioxide)

No events

Peto OR

8.89 (1.94, 40.64)

Peto OR

0.12 (0.01, 2.07)

Peto OR: Peto odds ratio, which was calculated for rare events (mortality, serious adverse events).

Figures and Tables -
Table 1. Sensitivity analysis by changing between worst‐case scenario analysis and best‐case scenario analysis for missing data
Comparison 1. Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Cardiopulmonary complications Show forest plot

2

140

Risk Ratio (M‐H, Fixed, 95% CI)

2.0 [0.38, 10.43]

2 Procedure‐related general complications Show forest plot

2

143

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.18, 5.71]

3 Analgesia requirements Show forest plot

3

193

Std. Mean Difference (IV, Random, 95% CI)

‐0.69 [‐1.42, 0.04]

3.1 Oxycodone (mg)

2

140

Std. Mean Difference (IV, Random, 95% CI)

‐0.97 [‐1.71, ‐0.22]

3.2 Ibuprofen (tablets/24 hours)

1

53

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.70, 0.38]

4 Cardiopulmonary changes Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

4.1 Heart rate (beats/minute)

1

100

Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐4.13, 2.93]

4.2 Mean arterial pressure (mmHg)

1

100

Mean Difference (IV, Fixed, 95% CI)

‐3.80 [‐7.90, 0.30]

4.3 Oxygen saturation (%)

1

100

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.39, 0.39]

4.4 Peak airway pressure (cm H2O)

1

100

Mean Difference (IV, Fixed, 95% CI)

‐0.30 [‐2.17, 1.57]

Figures and Tables -
Comparison 1. Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum
Comparison 2. Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Cardiopulmonary complications Show forest plot

3

128

Risk Ratio (M‐H, Fixed, 95% CI)

1.46 [0.35, 6.12]

2 Pneumoperitoneum‐related serious adverse events Show forest plot

3

128

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.28 [0.86, 80.03]

3 Pain scores (cm) (first postoperative day) Show forest plot

2

108

Mean Difference (IV, Fixed, 95% CI)

0.49 [‐0.28, 1.26]

4 Analgesia requirements (morphine mg) Show forest plot

1

90

Mean Difference (IV, Fixed, 95% CI)

12.0 [4.44, 19.56]

5 Number of participants requiring analgesia Show forest plot

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

0.42 [0.17, 1.04]

6 Cardiopulmonary parameters Show forest plot

3

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

6.1 Blood pH (start)

2

34

Mean Difference (IV, Fixed, 95% CI)

0.01 [‐0.01, 0.04]

6.2 Blood pH (middle)

3

52

Mean Difference (IV, Fixed, 95% CI)

‐0.00 [‐0.03, 0.02]

6.3 Blood pH (end)

2

34

Mean Difference (IV, Fixed, 95% CI)

0.10 [0.06, 0.14]

6.4 Partial pressure of carbon dioxide (mmHg) (start)

2

34

Mean Difference (IV, Fixed, 95% CI)

0.31 [‐1.79, 2.40]

6.5 Partial pressure of carbon dioxide (mmHg) (middle)

3

52

Mean Difference (IV, Fixed, 95% CI)

‐0.84 [‐3.70, 2.02]

6.6 Partial pressure of carbon dioxide (mmHg) (end)

2

34

Mean Difference (IV, Fixed, 95% CI)

‐12.78 [‐16.78, ‐8.77]

Figures and Tables -
Comparison 2. Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum
Comparison 3. Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Cardiopulmonary complications Show forest plot

1

146

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Pneumoperitoneum‐related serious adverse events Show forest plot

1

146

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Pain scores (cm) (first postoperative day) Show forest plot

1

146

Mean Difference (IV, Fixed, 95% CI)

‐0.8 [‐1.15, ‐0.45]

4 Hospital costs (CNY) Show forest plot

1

146

Mean Difference (IV, Fixed, 95% CI)

‐2667.0 [‐3275.68, ‐2058.32]

5 Cardiopulmonary parameters Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

5.1 Heart rate (beats/minute) (start)

1

146

Mean Difference (IV, Fixed, 95% CI)

‐0.10 [‐3.11, 2.91]

5.2 Heart rate (beats/minute) (middle)

1

146

Mean Difference (IV, Fixed, 95% CI)

‐7.30 [‐9.78, ‐4.82]

5.3 Heart rate (beats/minute) (end)

1

146

Mean Difference (IV, Fixed, 95% CI)

‐8.70 [‐11.72, ‐5.68]

5.4 Blood systolic pressure (mmHg) (start)

1

146

Mean Difference (IV, Fixed, 95% CI)

‐1.0 [‐5.12, 3.12]

5.5 Blood systolic pressure (mmHg) (middle)

1

146

Mean Difference (IV, Fixed, 95% CI)

2.80 [‐0.44, 6.04]

5.6 Blood systolic pressure (mmHg) (end)

1

146

Mean Difference (IV, Fixed, 95% CI)

‐2.0 [‐5.42, 1.42]

5.7 Partial pressure of carbon dioxide (mmHg) (start)

1

146

Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐1.39, 0.99]

5.8 Partial pressure of carbon dioxide (mmHg) (middle)

1

146

Mean Difference (IV, Fixed, 95% CI)

‐0.30 [‐1.37, 0.77]

5.9 Partial pressure of carbon dioxide (mmHg) (end)

1

146

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐1.43, 1.63]

Figures and Tables -
Comparison 3. Room air pneumoperitoneum versus carbon dioxide pneumoperitoneum
Comparison 4. Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Cardiopulmonary complications Show forest plot

2

143

Risk Ratio (M‐H, Fixed, 95% CI)

2.64 [0.64, 10.93]

2 Procedure‐related general complications Show forest plot

2

143

Risk Ratio (M‐H, Fixed, 95% CI)

1.82 [0.40, 8.31]

3 Pneumoperitoneum‐related serious adverse events Show forest plot

2

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.46 [0.47, 119.30]

4 Mortality Show forest plot

2

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.46 [0.47, 119.30]

Figures and Tables -
Comparison 4. Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data)
Comparison 5. Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Cardiopulmonary complications Show forest plot

2

143

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.27, 3.86]

2 Procedure‐related general complications Show forest plot

2

143

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.12, 2.58]

3 Pneumoperitoneum‐related serious adverse events Show forest plot

2

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.01, 2.19]

4 Mortality Show forest plot

2

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.01, 2.19]

Figures and Tables -
Comparison 5. Nitrous oxide pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data
Comparison 6. Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Cardiopulmonary complications Show forest plot

3

128

Risk Ratio (M‐H, Fixed, 95% CI)

4.58 [1.21, 17.36]

2 Procedure‐related general complications Show forest plot

4

144

Risk Ratio (M‐H, Fixed, 95% CI)

8.47 [1.11, 64.60]

3 Pneumoperitoneum‐related serious adverse events Show forest plot

3

128

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.19 [2.56, 33.01]

4 Mortality Show forest plot

4

144

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.89 [1.94, 40.64]

Figures and Tables -
Comparison 6. Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (worst/best‐case scenario analysis for missing data)
Comparison 7. Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Cardiopulmonary complications Show forest plot

3

128

Risk Ratio (M‐H, Fixed, 95% CI)

1.46 [0.35, 6.12]

2 Procedure‐related general complications Show forest plot

4

144

Risk Ratio (M‐H, Fixed, 95% CI)

0.2 [0.01, 3.61]

3 Pneumoperitoneum‐related serious adverse events Show forest plot

3

128

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.28 [0.86, 80.03]

4 Mortality Show forest plot

4

144

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.12 [0.01, 2.07]

Figures and Tables -
Comparison 7. Helium pneumoperitoneum versus carbon dioxide pneumoperitoneum (best/worst‐case scenario analysis for missing data